| pubmed-article:21980765 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21980765 | lifeskim:mentions | umls-concept:C0019196 | lld:lifeskim |
| pubmed-article:21980765 | lifeskim:mentions | umls-concept:C0681867 | lld:lifeskim |
| pubmed-article:21980765 | lifeskim:mentions | umls-concept:C0068788 | lld:lifeskim |
| pubmed-article:21980765 | lifeskim:mentions | umls-concept:C0017431 | lld:lifeskim |
| pubmed-article:21980765 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:21980765 | lifeskim:mentions | umls-concept:C0439234 | lld:lifeskim |
| pubmed-article:21980765 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21980765 | pubmed:dateCreated | 2011-10-10 | lld:pubmed |
| pubmed-article:21980765 | pubmed:abstractText | This study is an extension of an earlier, randomized; placebo-controlled that showed the efficacy of nitazoxanide (NTZ) 500 mg tablets twice daily for 6 months in treating HCV genotype 4. Access was available to 13/32 patients of the original study with chronic HCV during more than 3 years after the study was finished. One patient (with portal hypertension and oesophageal varices "O.V") was among 3 with SVR out of 9 of the NTZ treated patients suggesting that NTZ could successfully be used even in patients with O.V. SVR remain so up to the end of the follow-up period compared to none of the other 4 patients who received placebo. A fourth patient of NTZ group achieved virological response at the end of follow-up although she firstly showed RVR and then viral breakthrough. Most of the remaining patients of the NTZ group who did not achieve SVR showed variable partial response. No serious adverse events were reported in both groups during treatment and thereafter. | lld:pubmed |
| pubmed-article:21980765 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21980765 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21980765 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21980765 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21980765 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21980765 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21980765 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21980765 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21980765 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21980765 | pubmed:issn | 0253-5890 | lld:pubmed |
| pubmed-article:21980765 | pubmed:author | pubmed-author:KabilS MSM | lld:pubmed |
| pubmed-article:21980765 | pubmed:author | pubmed-author:YoussefS MSM | lld:pubmed |
| pubmed-article:21980765 | pubmed:author | pubmed-author:SolimanM SMS | lld:pubmed |
| pubmed-article:21980765 | pubmed:author | pubmed-author:MounierB IBI | lld:pubmed |
| pubmed-article:21980765 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21980765 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:21980765 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21980765 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21980765 | pubmed:pagination | 251-61 | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:meshHeading | pubmed-meshheading:21980765... | lld:pubmed |
| pubmed-article:21980765 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21980765 | pubmed:articleTitle | A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4. | lld:pubmed |
| pubmed-article:21980765 | pubmed:affiliation | Department of Hepatology, Gastroenterology & Infectious Diseases, Faculty of Medicine, University of Benha, Egypt. | lld:pubmed |
| pubmed-article:21980765 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21980765 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:21980765 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
